WO2007144081A3 - Raucherentwöhnungs-kombinationswafer - Google Patents

Raucherentwöhnungs-kombinationswafer Download PDF

Info

Publication number
WO2007144081A3
WO2007144081A3 PCT/EP2007/004937 EP2007004937W WO2007144081A3 WO 2007144081 A3 WO2007144081 A3 WO 2007144081A3 EP 2007004937 W EP2007004937 W EP 2007004937W WO 2007144081 A3 WO2007144081 A3 WO 2007144081A3
Authority
WO
WIPO (PCT)
Prior art keywords
nicotine
active ingredient
smoking withdrawal
combination
smoking
Prior art date
Application number
PCT/EP2007/004937
Other languages
English (en)
French (fr)
Other versions
WO2007144081A2 (de
Inventor
Hans-Rainer Hoffmann
Reto Braendli
Frank Theobald
Original Assignee
Lohmann Therapie Syst Lts
Hans-Rainer Hoffmann
Reto Braendli
Frank Theobald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts, Hans-Rainer Hoffmann, Reto Braendli, Frank Theobald filed Critical Lohmann Therapie Syst Lts
Priority to EP07725805A priority Critical patent/EP2029098A2/de
Priority to JP2009514662A priority patent/JP2009539893A/ja
Priority to BRPI0711996-8A priority patent/BRPI0711996A2/pt
Priority to US12/308,428 priority patent/US20100233244A1/en
Priority to CA002654477A priority patent/CA2654477A1/en
Publication of WO2007144081A2 publication Critical patent/WO2007144081A2/de
Publication of WO2007144081A3 publication Critical patent/WO2007144081A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die vorliegende Erfindung betrifft schnell zerfallende orale Darreichungsformen zur Applikation von Wirkstoffkombinationen zur Raucherentwöhnung mit einem Gehalt an Nikotin, einem Nikotinsalz, einem Nikotinderivat oder einem Stoff mit nikotinerger Wirkung, in Kombination mit einem weiteren Wirkstoff sowie die Verwendung solcher Darreichungsformen zur Behandlung der Nikotinabhängigkeit, zur Nikotinsubstitution oder zur Raucherentwöhnung und die Verwendung von Nikotin bzw. seiner Salze oder Derivate zur Herstellung von Arzneiformen zur Behandlung der Nikotinabhängigkeit. Der in Kombination zu verabreichende Wirkstoff ist dabei ein zentral wirkender Stoff , vorzugsweise ein Antidepressivums zur Bekämpfung der psychischen Abhängigkeit im Rahmen einer Raucherentwöhnungs-Therapie. Die Verabreichung der Wirkstoffkombination soll für den Patienten auf einfache und zuverlässige Weise erfolgen und Nebenwirkungen weitgehend ausschließen.
PCT/EP2007/004937 2006-06-16 2007-06-04 Raucherentwöhnungs-kombinationswafer WO2007144081A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP07725805A EP2029098A2 (de) 2006-06-16 2007-06-04 Raucherentwöhnungs-kombinationswafer
JP2009514662A JP2009539893A (ja) 2006-06-16 2007-06-04 組合せウェーハ
BRPI0711996-8A BRPI0711996A2 (pt) 2006-06-16 2007-06-04 preparaÇço farmacÊutica no formato de um folha, uso da preparaÇço farmacÊutica, uso de uma combinaÇço de agentes ativos, metodo para o tratamento terapÊutico de um individuo e mÉtodo para a produÇço de um forma de dosagem
US12/308,428 US20100233244A1 (en) 2006-06-16 2007-06-04 Smoking Withdrawal Combination Wafer
CA002654477A CA2654477A1 (en) 2006-06-16 2007-06-04 Smoking withdrawal combination wafer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006027795A DE102006027795A1 (de) 2006-06-16 2006-06-16 Raucherentwöhnungs-Kombinationswafer
DE102006027795.3 2006-06-16

Publications (2)

Publication Number Publication Date
WO2007144081A2 WO2007144081A2 (de) 2007-12-21
WO2007144081A3 true WO2007144081A3 (de) 2008-04-10

Family

ID=38662687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/004937 WO2007144081A2 (de) 2006-06-16 2007-06-04 Raucherentwöhnungs-kombinationswafer

Country Status (8)

Country Link
US (1) US20100233244A1 (de)
EP (1) EP2029098A2 (de)
JP (1) JP2009539893A (de)
CN (1) CN101472556A (de)
BR (1) BRPI0711996A2 (de)
CA (1) CA2654477A1 (de)
DE (1) DE102006027795A1 (de)
WO (1) WO2007144081A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586032T3 (es) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administración de composiciones de benzodiazepinas
ES2917973T3 (es) 2011-06-14 2022-07-12 Neurelis Inc Administración de benzodiacepina
US9687445B2 (en) 2012-04-12 2017-06-27 Lts Lohmann Therapie-Systeme Ag Oral film containing opiate enteric-release beads
CN103044307A (zh) * 2013-01-24 2013-04-17 吉林三善恩科技开发有限公司 以2,4-二羟基苯甲酸为前驱体的吡拉西坦药物共晶及其制备方法
CN104621327B (zh) * 2015-01-23 2018-03-16 广东工业大学 一种替烟口嚼糖及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000072A1 (en) * 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
WO2001080837A2 (de) * 2000-04-15 2001-11-01 Lts Lohmann Therapie-Systeme Ag Transdermale oder transmucosale darreichungsformen mit einer nicotinhaltigen wirkstoffkombination zur raucherentwöhnung
WO2002066016A2 (de) * 2001-02-19 2002-08-29 Lts Lohmann Therapie-Systeme Ag Mucoadhäsive zerfallsfähige arzneizubereitung
WO2002085119A1 (en) * 2001-04-20 2002-10-31 Lavipharm Laboratories Inc. Intraoral delivery of nicotine for smoking cessation
WO2004054551A1 (de) * 2002-12-05 2004-07-01 Lts Lohmann Therapie-Systeme Ag Filmförmige zubereitungen zur transmucosalen verabreichung von nicotin, sowie verfahren zu deren herstellung
WO2005004989A2 (en) * 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
EP1757279A1 (de) * 2005-08-22 2007-02-28 National Starch and Chemical Investment Holding Corporation Löslischer Film

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10224607B4 (de) * 2002-06-04 2008-03-13 Lts Lohmann Therapie-Systeme Ag Filmförmige, zerfallsfähige Zubereitungen zur Wirkstofffreisetzung und Verfahren zu deren Herstellung
DE10328942A1 (de) * 2003-06-27 2005-01-27 Lts Lohmann Therapie-Systeme Ag Transmukosale Darreichungsformen mit verminderter Schleimhautirritation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000072A1 (en) * 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
WO2001080837A2 (de) * 2000-04-15 2001-11-01 Lts Lohmann Therapie-Systeme Ag Transdermale oder transmucosale darreichungsformen mit einer nicotinhaltigen wirkstoffkombination zur raucherentwöhnung
WO2002066016A2 (de) * 2001-02-19 2002-08-29 Lts Lohmann Therapie-Systeme Ag Mucoadhäsive zerfallsfähige arzneizubereitung
WO2002085119A1 (en) * 2001-04-20 2002-10-31 Lavipharm Laboratories Inc. Intraoral delivery of nicotine for smoking cessation
WO2004054551A1 (de) * 2002-12-05 2004-07-01 Lts Lohmann Therapie-Systeme Ag Filmförmige zubereitungen zur transmucosalen verabreichung von nicotin, sowie verfahren zu deren herstellung
WO2005004989A2 (en) * 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
EP1757279A1 (de) * 2005-08-22 2007-02-28 National Starch and Chemical Investment Holding Corporation Löslischer Film

Also Published As

Publication number Publication date
DE102006027795A1 (de) 2007-12-20
CA2654477A1 (en) 2007-12-21
US20100233244A1 (en) 2010-09-16
EP2029098A2 (de) 2009-03-04
CN101472556A (zh) 2009-07-01
WO2007144081A2 (de) 2007-12-21
BRPI0711996A2 (pt) 2011-12-27
JP2009539893A (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
US20220304980A1 (en) Metered dosing compositions and methods of use of psychedelic compounds
BRPI0707235B1 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
WO2009127974A3 (ko) 심혈관계 질환 치료용 약제학적 제제
WO2004112711A3 (en) Oral extended-release composition
NZ605469A (en) Nalbuphine-based formulations and uses thereof
JP2019517542A5 (de)
US10022449B2 (en) Synergistic antiviral composition and use thereof
RU2011138490A (ru) Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
ES2236551T3 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
WO2007144081A3 (de) Raucherentwöhnungs-kombinationswafer
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2008051527A3 (en) Sustained release of agents for localized pain management
JP2011500589A5 (de)
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
ES2959880T3 (es) Productos libres de tabaco y humo consumibles por seres humanos como productos epicúreos o médicos y procedimiento de tratamiento de la adicción al tabaco
KR101896441B1 (ko) 국소투여형의 연하장애 개선용 의약품
RU2011113733A (ru) Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
TW200626133A (en) Oral medication for twice-daily administration
WO2011035343A3 (en) Phentermine liquid dosage form

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780022502.2

Country of ref document: CN

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07725805

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2654477

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007725805

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009514662

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: PI0711996

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081215